63 yrs old lady with htn,dm,cardiac illness, osteoarthritis and depression with somatic symptoms since 10.yrs. Multiple treatment with failure earlier sertraline, escitalopram, amisulpiride,ketamine Last on venalafaxine 150, mirtazapine 15,quitapine 25, clonazepam 0.5, since last 8 months maintaining well Since last month, restlessness,pain in chest, legs, disturbed sleep, venalafaxine raised to 225, quitapine 100, mirtazapine 15, Gabapentin 200 Has restlessness, generalised unease,only improved sleep,but restless What pharmacological management according to NICE or APA guidelines
Reading Document
Medical Text Search
treatment resistant depression pharmacological management NICE APA guidelines augmentation strategies
Medical Text Search
somatic symptom disorder depression comorbidity venlafaxine mirtazapine quetiapine management
GradeResponse
GradeResponse
Now let me synthesize a comprehensive, clinically structured answer from the retrieved sources, supplemented by NICE/APA guideline knowledge.
Pharmacological Management — Treatment-Resistant Depression with Somatic Symptoms
Clinical Formulation
This lady has treatment-resistant depression (TRD) with somatic symptom disorder (SSD), complicated by:
- Multiple comorbidities: HTN, DM, cardiac illness, osteoarthritis
- Prior failures: sertraline, escitalopram, amisulpride, ketamine
- Current regimen: venlafaxine 225 + mirtazapine 15 + quetiapine 100 + clonazepam 0.5 + gabapentin 200
- Persistent symptoms: restlessness, chest pain, leg pain, generalised unease (sleep now improved)
Critical Step First: Rule Out Akathisia
The constellation of restlessness + generalised unease + worsening after venlafaxine increase is highly consistent with drug-induced akathisia, which can be caused or worsened by:
- Venlafaxine dose escalation (serotonergic akathisia)
- Quetiapine increase (dopaminergic blockade)
This must be differentiated from agitated depression relapse before further dose escalation, as escalating the offending drug worsens akathisia.
| Feature | Akathisia | Agitated Depression |
|---|---|---|
| Inner restlessness | ++ | ++ |
| Need to move legs/body | ++ | + |
| Worse after drug increase | Yes | No |
| Subjective distress out of proportion | Yes | Variable |
| Sleep response to current regimen | Improved (as here) | Usually still disturbed |
Step 1: Address Akathisia (If Present)
Per APA Practice Guidelines and Maudsley Prescribing Guidelines:
- Reduce venlafaxine back to 150 mg (causative dose increase)
- Propranolol 10–30 mg BD — first-line for drug-induced akathisia (non-selective beta-blocker; use with caution given cardiac history — assess HR, BP, and contraindications first)
- Clonazepam (already prescribed at 0.5 mg) provides some benefit; can increase cautiously to 0.5 mg BD if needed
- Mirtazapine 15–30 mg — already on board; has anti-akathisia properties via 5-HT2A antagonism — consider increasing to 30 mg rather than escalating venlafaxine
Step 2: Optimise Current Regimen
Venlafaxine
- NICE CG90 (Depression in Adults) and APA 2010/2023 guidelines: Once partial response is established on a dose, dose escalation above 225 mg offers limited additional benefit and increases side effect burden
- At 225 mg, SNRI noradrenergic effect is maximal; further increase not recommended without specialist review
Mirtazapine
- Currently at 15 mg (sedating, antihistaminergic dose) — increase to 30–45 mg to access antidepressant + serotonergic + somatic pain benefits
- California Rocket Fuel (venlafaxine + mirtazapine) is an evidence-based combination; ensure it is optimised before adding agents
Quetiapine
- At 100 mg (antipsychotic/augmentation dose) — quetiapine-XR is FDA-approved and NICE-recognised for MDD augmentation (Management of MDD, p.46)
- For somatic symptoms and anxiety, 50–150 mg range is appropriate; going above 100 mg risks worsening metabolic profile (concern in DM + cardiac disease)
Gabapentin 200 mg
- Subtherapeutic for neuropathic pain (therapeutic range: 900–3600 mg/day in divided doses)
- NICE NG193 (Chronic pain): gabapentinoids are recommended for neuropathic/chronic pain
- Can titrate to 300–600 mg TDS for osteoarthritis pain and somatic pain components — this may resolve leg pain and reduce overall unease significantly
Step 3: Augmentation Options per NICE/APA
| Agent | Evidence Base | Consideration in This Patient |
|---|---|---|
| Lithium augmentation | NICE CG90 first-line augmentation for TRD | Requires monitoring; caution with renal function, HTN drugs (NSAIDs interaction); but strong evidence |
| Aripiprazole 2–10 mg | FDA-approved, APA recommended for TRD augmentation | Better metabolic profile than quetiapine; may worsen akathisia — avoid if akathisia present |
| Brexpiprazole 1–3 mg | FDA-approved (2023), lower akathisia risk than aripiprazole | Preferred SGA augmentation if akathisia is ruled out |
| Lamotrigine 25–100 mg | Maudsley/NICE for TRD augmentation, especially with somatic symptoms | Good tolerability; titrate slowly; helpful for pain comorbidity |
| Duloxetine (replace venlafaxine) | NICE NG193 for chronic pain + depression | Duloxetine 60–120 mg has stronger evidence for pain + depression than venlafaxine — consider switch if somatic pain dominates |
Step 4: Address Somatic Symptom Disorder Pharmacologically
Per Harrison's (p.12889): SSD with depression comorbidity affects severity and functional outcomes; treatment targets both.
- Duloxetine (SNRI with pain license) > venlafaxine for comorbid pain + depression per NICE NG193
- Low-dose tricyclic (amitriptyline 10–25 mg): NICE-recommended for chronic pain, but cardiac conduction effects require ECG clearance in this lady
- Gabapentin optimisation (as above) addresses both neuropathic pain and somatic amplification
Practical Prioritised Action Plan
- Assess for akathisia (Barnes Akathisia Rating Scale) — if present, reduce venlafaxine to 150 mg and add propranolol (with cardiac caution)
- Increase mirtazapine to 30 mg — optimises the existing combination, adds anti-akathisia and analgesic benefit
- Titrate gabapentin to 300 mg TDS — addresses leg pain, osteoarthritis, somatic unease
- Consider switching venlafaxine to duloxetine 60–90 mg if somatic pain is dominant — better NICE NG193 evidence for pain-depression comorbidity
- Lithium augmentation — per NICE CG90, first-line for TRD; discuss with patient, monitor renal function and drug interactions
- Avoid aripiprazole until akathisia is excluded; if needed, prefer brexpiprazole
- Review clonazepam — long-term benzodiazepine in elderly with DM + cardiac disease: NICE recommends structured dose reduction; clonazepam not recommended long-term
Important Safety Flags in This Patient
- Cardiac illness: avoid high-dose QTc-prolonging agents (quetiapine >100 mg, TCAs); baseline ECG mandatory before any dose change
- DM: quetiapine and mirtazapine worsen glycaemic control — review HbA1c
- HTN: lithium + ACE inhibitors/ARBs significantly raises lithium levels — monitor closely
- Age 63: gabapentin causes dizziness/fall risk; titrate slowly
- Clonazepam: NICE and BNF recommend against long-term use in this age group — plan a slow taper once mood stabilises
This is a shared conversation. Sign in to Orris to start your own chat.